SCHEMBL22290248

SCHEMBL22290248

O=C1c2ccccc2C(=O)N1Cc1nccnc1-c1ccc(F)cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.56
CYP2C19 P33261 1/20 0.56
CASP3 P42574 1/20 0.50
ALDH1A1 P00352 5/20 0.47
MEN1 O00255 1/20 0.47
PKM P14618 1/20 0.47
KMT2A Q03164 1/20 0.47
NPC1 O15118 1/20 0.46
RAB9A P51151 1/20 0.46
GRM5 P41594 2/20 0.45
RPS6KA2 Q15349 1/20 0.44
LMNA P02545 1/20 0.43
HPGD P15428 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
POLB P06746 1/20 0.41
MMP2 P08253 1/20 0.41
MMP9 P14780 1/20 0.41
ADRA1D P25100 1/20 0.39
ADRA1A P35348 1/20 0.39
ADRA1B P35368 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22290217 0.81 CYP1A2 (0.50) CYP1A2CYP2C19CASP3ALDH1A1MEN1
SCHEMBL22290264 0.76 CASP3 (0.48) CYP1A2CYP2C19CASP3ALDH1A1MEN1
SCHEMBL4424799 0.74 CASP3 (0.79) CYP1A2CYP2C19CASP3ALDH1A1RPS6KA2
SCHEMBL22309089 0.74 CASP3 (0.49) CYP1A2CYP2C19CASP3ALDH1A1MEN1
SCHEMBL26963703 0.73 ALDH1A1 (0.54) CASP3ALDH1A1MEN1PKMKMT2A
SCHEMBL29940891 0.73 ALDH1A1 (0.54) CASP3ALDH1A1MEN1PKMKMT2A
SCHEMBL399990 0.73 ALDH1A1 (0.54) CYP1A2CYP2C19CASP3ALDH1A1MEN1
SCHEMBL2644044 0.72 CASP3 (0.87) CYP1A2CYP2C19CASP3ALDH1A1NPC1
SCHEMBL4417314 0.71 CASP3 (0.59) CYP1A2CYP2C19CASP3ALDH1A1NPC1
SCHEMBL1777850 0.71 KDM4E (0.55) CYP1A2CYP2C19CASP3ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210387968-A1 HETEROARYLMETHYLENE DERIVATIVES AS DNA POLYMERASE THETA INHIBITORS IDEAYA BIOSCIENCES INC (US) 2021-12-16 US disclosed
EP-3917919-A1 HETEROARYLMETHYLENE DERIVATIVES AS DNA POLYMERASE THETA INHIBITORS Ideaya Biosciences, Inc. (US) 2021-12-08 EP disclosed
WO-2020160213-A1 HETEROARYLMETHYLENE DERIVATIVES AS DNA POLYMERASE THETA INHIBITORS IDEAYA BIOSCIENCES, INC. (US) 2020-08-06 WO disclosed
WO-2020160213-A1 HETEROARYLMETHYLENE DERIVATIVES AS DNA POLYMERASE THETA INHIBITORS IDEAYA BIOSCIENCES, INC. (US) 2020-08-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210387968-A1 HETEROARYLMETHYLENE DERIVATIVES AS DNA POLYMERASE THETA INHIBITORS POLQ, POLH, POLB CYP1A2 931/4885CYP2C19 938/4885CASP3 3863/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.